Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
Small nuclear ribonucleoprotein polypeptide C pseudogene 4" (SNRPCP4) refers to a *pseudogene* derived from the gene encoding the C polypeptide of small nuclear ribonucleoproteins (snRNPs), which are components of the spliceosome machinery responsible for precursor mRNA splicing. Pseudogenes are non-functional segments of DNA that arise from gene duplication or retrotransposition events but typically do not encode functional proteins. There is no evidence that this pseudogene produces a functional protein or is involved in biological processes or diseases. It is not considered a therapeutic target, receptor, enzyme, transporter, or biologically active molecule relevant to drug discovery efforts. No known drugs, biomarkers, or safety concerns are associated with this pseudogene. **Key points:** - SNRPCP4 is a pseudogene, not an active gene or protein, and thus is not a drug target or receptor. - No biological, molecular, or clinical function has been assigned to SNRPCP4 in the available literature. - There are no established aliases, interacting drugs, or safety/toxicological considerations. - There is no evidence of a role in any disease, nor any reported use as a biomarker. **Note on potential confusion:** The query may stem from confusion with *SNRPC* (small nuclear ribonucleoprotein polypeptide C), which is a functional protein component of the spliceosome, or with small nuclear RNAs (snRNAs) and their role in splicing and neurodevelopmental disorders[1][2]. However, SNRPCP4 specifically denotes a non-functional pseudogene, not those active elements.
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on Small nuclear ribonucleoprotein polypeptide C pseudogene 4 (SNRPCP4).